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ABSTRACT
Oestrogen receptor (ER) is the driving transcrip-
tion factor in 70% of breast cancer. Endocrine
therapies targeting the ER represent one of the
most successful anticancer strategies to date. In
the clinic, novel targeted agents are now being
exploited in combination with established
endocrine therapies to maximise efficacy. How-
ever, clinicians must balance this gain against
the risk to patients of increased side effects with
combination therapies. This article provides a
succinct outline of the principles of hormonal
manipulation in breast cancer, alongside the key
evidence that underpins current clinical practice.
As the role of endocrine therapy in breast cancer
continues to expand, the challenge is to inter-
pret the data and select the optimal strategy for a
given clinical scenario.
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INTRODUCTION
Oestrogen receptor (ER) is the driving tran-
scription factor in around 70% of breast cancer
[1]. Circulating oestrogen (17b-estradiol, E2)
binds to the ligand-binding domain of ER in
breast cancer cells. The E2–ER complex then
forms a dimer and binds to oestrogen response
elements (EREs) on the DNA in the cell nucleus.
This process activates a set of ER target genes
which ultimately lead to cell cycle progression
and tumour proliferation [2].
Endocrine therapy is the mainstay of
treatment for patients with invasive breast car-
cinoma that is positive by immunohistochem-
istry for ER protein expression (ER?). The
foundation stone for current practice was laid in
the late nineteenth century by George Beatson,
who found that removal of the ovaries
(oophorectomy) improved outcomes for
women with advanced breast cancer—even
before the hormone, oestrogen, was discovered
[3]. More than half a century later, the nuclear
receptor ER itself was discovered, thereby pro-
viding a mechanism for the tissue specificity of
oestrogen action [4].
Today, endocrine therapy such as tamoxifen
and aromatase inhibitors represent one of the
most effective targeted cancer therapies to reach
the clinic. Other established targeted agents in
ER? breast cancer are used largely in combina-
tion with endocrine therapy. These include
monoclonal antibodies, tyrosine kinases,
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mammalian target of rapamycin (mTOR) inhi-
bitors and cyclin-dependent kinase 4/6 (CDK4/
6) inhibitors.
The clinical challenge now is to identify the
right drug or therapy combination for the right
patient for use at the right time. The aim is for
individual patients to gain maximal benefit
from endocrine therapy without incurring
excessive toxicity.
This review is written as a resource for clini-
cians in training, scientists and Masters level
students of oncology. This article is based on
previously conducted studies, some of which
were performed by the authors in full compli-
ance with ethics guidelines. The article does not
contain any studies with animals performed by
either of the authors.
TARGETING THE OESTROGEN
RECEPTOR PATHWAY
Hormonal manipulation of oestrogen signalling
via ER is achieved in a variety of ways in the
treatment of breast cancer. The main strategies
are oestrogen deprivation using aromatase
inhibitors (AIs), and blocking the binding
between oestrogen and ER using selective
oestrogen receptor modulators (SERMs) or
downregulators (SERDs). Hormonal manipula-
tion may also be achieved with surgery and
radiotherapy, although these modalities have
largely been replaced by pharmacological
strategies. Endocrine therapy is inherently less
toxic than chemotherapy, which is not targeted
on the ER. However, pharmacological strategies
targeting an active ER have a range of adverse
effects that can cause significant morbidity and
even be life-threatening.
The choice of endocrine therapy in a given
clinical context is a factor of age, menopausal
status, co-morbidities and the drug toxicity
profile. A balance between efficacy and tolera-
bility (or toxicity) should be considered.
Tamoxifen is a SERM that competes with
oestrogen for binding to the ligand binding
domain of ER [5]. It is useful as a single agent for
both pre- and postmenopausal patients [6].
In breast cancer tissue, tamoxifen-bound ER
binds to the same genomic binding sites as
oestrogen-bound ER. However, target genes are
regulated in the opposite direction, with the
downstream effect being reduced proliferation
of tumour cells (ER antagonism) [5].
In other tissues, such as the endometrium,
tamoxifen acts as a partial agonist. This is likely
due to differential recruitment of co-activators
and co-repressors to the ER transcription com-
plex. In endometrial cells, tamoxifen-bound ER
regulates ER target genes in the same direction
as oestrogen-bound ER, leading to upregulated
proliferation. Patients on tamoxifen for ER?
breast cancer increase their baseline risk of
developing endometrial carcinoma by a factor
of 2–3 [7].
Other potentially life-threatening adverse
effects of tamoxifen include venous and arterial
vascular events such as pulmonary embolism
and stroke, whilst hot flushes impair quality of
life and limit adherence to treatment [6].
Despite this, tamoxifen is generally well toler-
ated, with a side effect profile established over
40 years of use.
For postmenopausal women, endocrine
therapy with third-generation aromatase inhi-
bitors (AIs) such as anastrozole, letrozole and
exemestane has now become the preferred
choice over tamoxifen [8]. Aromatase inhibition
decreases the peripheral conversion of andro-
gens to oestrogen, thereby cutting off the
tumour’s fuel supply [9]. Anastrozole and
letrozole are non-steroidal AIs. As a result of
incomplete cross-resistance between steroidal
and non-steroidal AIs, switching from anastro-
zole or letrozole to exemestane (or vice versa)
may lead to change in disease response and/or
toxicity [10].
Like tamoxifen, AIs are generally very well
tolerated drugs with known toxicity profile.
However, bone demineralisation and muscu-
loskeletal side effects such as arthralgia cause
significant treatment-related morbidity [11].
Fulvestrant is a selective ER downregulator.
Like tamoxifen, it targets an active ER, but has a
distinct mechanism of action [12]. Once bound,
fulvestrant leads to ER degradation and loss of
ER protein expression, which has been shown to
be dose-dependent in a presurgical study (see
Fig. 1) [13].
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Fulvestrant has no known agonist activity,
which avoids many of the pro-thrombotic and
pro-proliferative side effects of tamoxifen. The
side effect profile of fulvestrant also compares
favourably with standard of care AIs, and causes
fewer musculoskeletal side effects, as shown in
the pivotal phase 3 trial comparing it with
anastrozole (see Table 1) [14]. In contrast to AIs,
which are known to be deleterious to bone
mineral density, prospective clinical data with
18 months of follow-up indicate that fulves-
trant does not increase bone turnover markers
[15].
Newer targeted agents in current clinical use
for ER? breast cancer include mTOR inhibitors
and CDK4/6 inhibitors. Although used in con-
junction with endocrine therapies, both are
purported to have specific activity in
ER? disease.
Mammalian target of rapamycin is a serine/
threonine kinase downstream of phos-
phatidylinositol 3-kinase (PI3K)–Akt. Crosstalk
between the PI3K–Akt–mTOR pathway and ER
signalling is an evolving field. It is suggested
that S6 kinase 1, a substrate of mTOR complex 1
(mTORC1), phosphorylates the activation
function domain 1 of the ER leading to consti-
tutive activity of ER [16]. By this mechanism,
mTOR inhibition is claimed to have an indirect
but specific effect on ER activity. Common side
effects of mTOR inhibitors include rash, stom-
atitis, fatigue, diarrhoea and altered taste
(dysgeusia).
The link between cyclin-dependent kinase
4/6 inhibitors and ER activity is mechanistically
less clear. Oncogenic pathways in ER? breast
cancer, e.g. PI3K–Akt–mTOR, ultimately con-
verge on the cell cycle to drive cell proliferation.
CDK4 and 6 form a cell cycle regulatory path-
way with p16, cyclin D and the gatekeeper
protein, retinoblastoma (Rb). CDK4/6 inhibitors
bind to CDK4 and CDK6, preventing phospho-
rylation of the Rb protein. This halts cell cycle
progression and induces G1 cell cycle arrest
Fig. 1 Progressive reduction in post-treatment ER levels with increasing dose of fulvestrant. FAS Faslodex (fulvestrant),
SEM standard error of the mean Reprinted from Ref. [13]. Copyright (2014), with permission from Elsevier
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[17]. It is thought that resistance to endocrine
therapy may occur because of cyclin D overex-
pression and retinoblastoma phosphorylation,
making CDK4/6 inhibition an attractive strat-
egy to improve outcomes for patients with
hormone receptor-positive disease. Not surpris-
ingly, the side effect profile of CDK4/6 inhibi-
tors overlaps with other inhibitors of cell cycle
progression, including chemotherapeutic
agents. These include potentially life-threaten-
ing complications secondary to neutropenia.
However, in contrast to that seen with
chemotherapy, it is thought that such neu-
tropenia is stem cell independent, less pro-
longed and less associated with febrile
neutropenia [18].
ADVANCED DISEASE
In the advanced (non-curative) disease setting,
endocrine therapy is used to control disease
progression and improve survival. The princi-
ples of hormonal manipulation are best descri-
bed in this setting because the tumour remains
in situ, and the response to hormonal manipu-
lation can usually be measured. Furthermore,
since advanced disease carries a poor prognosis
compared to early, non-metastatic disease, a
shorter follow-up is required to reach primary
endpoints in clinical trials. For these reasons,
most drug development studies begin in this
clinical context. It is generally only after both
efficacy and tolerability have been shown to be
satisfactory in the advanced setting that the
potential use of new agents can be explored in
the adjuvant setting.
Response to endocrine therapy in the
advanced setting is assessed using established
objective assessment criteria such as Response
Evaluation Criteria in Solid Tumours (RECIST)
and Union for International Cancer Control
(UICC) (see Table 2).
Clinical benefit is a key principle in endo-
crine therapy decision-making in advanced
ER? disease. Patients will be commenced on the
best agent first. After 6 months of treatment,
patients who have stable disease (SD) derive the
same survival advantage as those who achieve
an objective response (OR), compared to those
who have progressive disease (PD) [19]. Patients
with OR/SD at 6 months are therefore consid-
ered to have derived clinical benefit and can
continue the same treatment until progression.
Patients with PD at 6 months can be con-
sidered as having intrinsic/de novo resistance to
endocrine therapy. For these patients, the
chance of deriving benefit to further endocrine
manipulation is relatively low. This can, how-
ever, be optimised by selecting a sequential
therapy with an alternative mechanism of
action to minimise cross-resistance.
Table 1 Tolerability of fulvestrant is similar to anastrozole but causes less musculoskeletal side effects. Modiﬁed with
permission from Ref. [14]
Number of adverse events (%)
Fulvestrant Anastrozole p value
Hot ﬂushes 89 (21.0) 87 (20.6) 0.91
GI disturbance 196 (46.3) 185 (43.7) 0.53
Weight gain 4 (0.9) 7 (1.7) 1.35
Vaginitis 11 (2.6) 8 (1.9) 0.51
Thromboembolic disease 15 (3.5) 17 (4.0) 0.68
Joint disorders 23 (5.4) 45 (10.6) 0.0036
Urinary tract infection 31 (7.3) 18 (4.3) 0.062
Withdrawn due to AE 12 (2.8) 8 (1.9)
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Patients with CB at 6 months will eventually
experience disease progression due to acquisi-
tion of secondary resistance mechanisms.
Compared to de novo progressors, however, the
chance of deriving benefit from sequential
endocrine manipulation is relatively high.
Patients who present with advanced
ER? disease can be new patients or pre-existing
breast cancer patients whose disease has
relapsed despite adjuvant therapy (a failure of
adjuvant treatment). Initial therapy for
advanced disease is based upon prior use of
endocrine therapy in the adjuvant setting. The
clinical focus of treatment in the non-curative
setting is on quality of life. Endocrine therapy,
being efficacious and generally well tolerated, is
therefore the default treatment.
There are, however, certain circumstances in
which chemotherapy is used first-line in
advanced ER? disease instead of endocrine
therapy. Firstly, where there is imminently life-
threatening disease, e.g. extensive liver metas-
tases or pulmonary lymphangitic spread with
dyspnoea, chemotherapy can be used to provide
more rapid disease control. Secondly, if endo-
crine resistance is likely (e.g. weak ER positivity,
or no CB with prior endocrine therapy) single
agent chemotherapy may be used.
Ovarian suppression in combination with
endocrine therapy is a rational combination in
premenopausal patients. Luteinising hormone
releasing hormone analogue (LHRHa) therapy
such as goserelin increases negative feedback on
the pituitary, reducing the production of
gonadotrophins.
In premenopausal women with advanced
ER? disease, LHRHa therapy can be used first-
line to suppress ovarian production of oestro-
gen. Goserelin is used in combination with
tamoxifen, provided tamoxifen has not previ-
ously been used in the adjuvant setting. There is
also evidence that LHRHa therapy in combina-
tion with aromatase inhibition works clinically
and biochemically [20].
In postmenopausal women with advanced
ER? disease, a third-generation AI (anastrozole,
letrozole or exemestane) is superior to tamox-
ifen [21–23]. As an example, direct comparison
with tamoxifen showed that anastrozole
extends median time to progression by
4 months [24].
Targeted drugs that can be used in combi-
nation with endocrine therapy include CDK4/6
and mTOR inhibitors. These treatment options
were incorporated into clinical guidelines fol-
lowing clinical trials data showing an additional
6 months of progression-free survival with
mTOR inhibition (using everolimus plus AI),
and 10 months with CDK4/6 inhibition (using
palbociclib plus AI) [16, 25] compared to AI
monotherapy.
Combination of an AI and CDK4/6 inhibitor
has become standard first-line endocrine ther-
apy in metastatic hormone receptor-positive
breast cancer [26]. There are now three CDK4/6
inhibitors licensed in this setting: palbociclib
[25], ribociclib [27] and abemaciclib [28]. The
benefit over single agent AI therapy is not dis-
puted but must be weighed against significant
increase in toxicity when used in combination
Table 2 Assessment of responses (UICC)
Complete response (CR) No measurable disease
Partial response (PR) Reduction of at least 50% in maximal dimension
Objective response (OR) CR or PR
Stable disease (SD) No change
Progressive disease (PD) Increase of at least 25% in maximal dimension, or new disease
Clinical beneﬁt (CB) OR ? SD at or beyond 6 months
U/A Unassessable
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with CDK4/6 or mTOR inhibition, and patients
must be selected accordingly.
Where combination therapy is not an
option, fulvestrant 500 mg may be used as sole
therapy [14, 29]. Trials of fulvestrant use in first-
line advanced ER? breast cancer included the
FIRST (phase 2) and FALCON (phase 3) trials
[30, 31]. Whilst the phase 2 FIRST trial was not
sufficiently powered to prove benefit, the phase
3 FALCON trial demonstrated superiority of
fulvestrant over anastrozole (median PFS 16.6
versus 13.8 months) and led to fulvestrant being
licensed for first-line use.
In second-line treatment, for patients who
have not received prior CDK4/6 inhibitor and
who have progressed on endocrine therapy, the
preferred option is fulvestrant plus a CDK4/6
inhibitor [32]. An alternative option for second-
line treatment following progression on AI is
combination therapy with an mTOR inhibitor,
everolimus [16].
Combination of fulvestrant with an AI has
also been explored in clinical trials (see Table 3).
This approach of combining ER antagonism
(with SERM or SERD) with oestrogen depriva-
tion (with AI) is known as ‘‘maximal endocrine
therapy’’. However, additional benefit of the
combination versus single agent therapy has
been difficult to demonstrate, which may be
due to prior adjuvant endocrine therapy usage
(see Table 3). No difference is seen in both the
SoFEA and FACT studies, in which most patients
(around 70%) had received prior endocrine
therapy [33, 34]. In the later SWOG 0226 study,
a smaller proportion of patients (around 40%)
had been treated with adjuvant endocrine
therapy. The SWOG study found a significant
improvement in PFS for patients who received
the combination [35].
In patients with hormone receptor-positive
disease that also overexpresses the HER2 recep-
tor, endocrine therapy and HER2-targeted
therapy can be used either sequentially or in
combination. Comparison of these approaches
was made in the Tandem study, which reported
that trastuzumab plus anastrozole improves
progression-free survival by a factor of 2, albeit
from a low baseline of 2.4 months, up to
4.8 months (p = 0.0016) [36]. However, this
benefit came with significant cost in toxicity,
with increase from 16% to 28% in grade 3 or 4
toxicities with use of the combination.
ADJUVANT ENDOCRINE THERAPY
In the curative setting, endocrine therapy is
given as ‘adjuvant’ treatment for up to 10 years
following definitive surgery, to reduce the risk
of disease recurrence (relapse) for patients with
ER? breast cancer. Additional chemotherapy is
often used in patients with higher risk of relapse
as determined by Nottingham Prognostic Index
and other clinical risk stratification tools such as
Adjuvant Online, Predict and Oncotype DX
[37–39].
Choice of endocrine therapy drug in the
adjuvant setting depends primarily on meno-
pausal status. Tamoxifen as an adjuvant therapy
works in pre- and postmenopausal women.
Premenopausal women, in whom levels of
circulating oestrogen are higher as a result of
Table 3 Maximal endocrine therapy: effect of prior endocrine therapy
SoFEAa FACTb SWOG 0226c
Design [F = fulvestrant (250 mg with loading dose);
A = anastrozole; E = exemestane]
F ? A vs F (vs E) F ? A vs A F ? A vs A
HP for PFS or TTP 1.00 0.99 0.81
Prior anti-oestrogen - 70% - 67% - 40%
HR hazard ratio, PFS progression-free survival, TTP time to progression
a Johnston et al. [33]
b Bergh et al. [34]
c Mehta et al. [35]
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endocrine production by the ovaries, are given
tamoxifen to block the ER.
Premenopausal patients at higher risk of
recurrence, in whom chemotherapy is indi-
cated, are offered tamoxifen in combination
with ovarian suppression [40]. The ZEBRA trial
demonstrated that for women at higher risk
who choose not to have chemotherapy, this
approach can be an effective alternative. How-
ever, as a result of the date of the study, the
comparison in ZEBRA was not made with
modern chemotherapy regimes. More recently,
the SOFT trial found that all women at higher
risk of recurrence benefit further from subse-
quent ovarian suppression plus endocrine
therapy following completion of chemotherapy
[41].
In postmenopausal women, oestrogen is
derived primarily from extra-gonadal sources.
Inhibition of peripheral production of oestro-
gen via CYP19 (aromatase) using AIs has proved
marginally more effective than blocking the ER
with tamoxifen in postmenopausal women
[11]. This conclusion has been reached on the
basis of a collective view of all the adjuvant
trials comparing the previous gold standard of
5 years of tamoxifen with AIs, with the latter
approach demonstrating superiority both in
terms of efficacy and tolerability [42]. The main
concern of long-term (adjuvant) use of AIs is on
bone mineral density (BMD). To prevent harm
due to loss of BMD, patients receiving AIs will
have BMD checked at baseline, monitored reg-
ularly and managed if required using oral bis-
phosphonate medication.
Sequential and extended use of tamoxifen
and AIs has been extensively explored (see
Fig. 2).
In practice, menopausal status is often diffi-
cult to define, and a ‘perimenopausal’ status
exists. This is further complicated by use of
adjuvant chemotherapy that can cause men-
strual cycles to cease, either temporarily or
permanently. Pragmatic use of sequential
tamoxifen and AI is often employed, backed by
good evidence of equivalent effectiveness [43].
Strategies to define menopausal status may
include measurement of circulating oestradiol
and follicle-stimulating hormone levels.
Extended use of endocrine therapy has
proved effective in further reducing rates of
recurrence beyond the 5-year point, as demon-
strated by pivotal studies such as MA17R,
ATTOM and ATLAS [44–46]. In the clinic, this
tends to be decided on a case-by-case basis
depending on tolerability of endocrine therapy
and risk of disease recurrence—especially dis-
tant metastases where the treatment intent will
usually change to non-curative (i.e. palliative).
The impact of prolonged endocrine therapy is
most apparent from these studies when con-
sidering disease-free survival (DFS), which
includes all events including local, regional and
contralateral disease. However, there is a
demonstrable but modest benefit on distant
recurrence-free and overall survival, which
continues beyond the 10 years of treatment.
NEOADJUVANT ENDOCRINE
THERAPY
Chemotherapy can also be given prior to sur-
gery, as a ‘neoadjuvant’ treatment with the aim
of downstaging the primary tumour so that
breast-conserving surgery can be performed (by
wide local excision) instead of mastectomy.
Neoadjuvant therapy was originally pro-
posed following work performed on a mouse
model, which indicated that manipulation of
the primary tumour leads to growth and dis-
semination of metastases [47]. The hypothesis
was that neoadjuvant chemotherapy given to
patients with primary breast cancer would treat
undetectable metastases (micro-metastases) and
thereby improve survival. However, the pivotal
trial NSABP-B18 showed no difference in sur-
vival between chemotherapy given in the
adjuvant and neoadjuvant settings [48]. This
could be related to the fact that chemotherapy,
as a result of its toxicity and immunosuppres-
sive effects, could not be given during the
perioperative period—the crucial period in
terms of tumour manipulation.
In contrast, it is possible to give endocrine
therapy in the perioperative period. While there
is a concern that tamoxifen may further
increase the risk of venous thromboembolism
(VTE) during this period of high VTE risk, this
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would be avoided with the use of AIs or fulves-
trant. In the neoadjuvant setting, the superior-
ity of AIs over tamoxifen has been well
established, and fulvestrant is also under
investigation [49–52]. Both of these agents have
a potential role in tumour downstaging to
increase rates of breast-conserving surgery.
However, whilst it can downstage primary
ER? breast cancer, with less toxicity than
chemotherapy, neoadjuvant endocrine therapy
has not been widely adopted because of con-
cerns about de novo (intrinsic) resistance to
hormonal manipulation. Progression during
neoadjuvant endocrine therapy would in theory
put patients at increased risk of disease recur-
rence following surgery, and reduce rates of
downstaging (or even operability) compared to
those who undergo surgery upfront. Intrinsic
resistance is found across multiple studies in the
setting of primary and neoadjuvant endocrine
therapy (see Fig. 3) [53]. These studies showed a
rate of initial disease progression of up to 30%,
which is not comparable to that of neoadjuvant
chemotherapy (around 3%) [54]. Most of these
studies used tamoxifen, and response rates
would be expected to improve with use of AIs or
fulvestrant. However, compared to chemother-
apy, recent evidence suggests that giving endo-
crine therapy in the neoadjuvant setting is
associated with lower rates of downstaging and
complete response [55]. Use of decision-making
tools such as Oncotype Dx has been explored to
help choose neoadjuvant therapy for breast
cancer. For example, for patients with low or
intermediate recurrence risk according to the
Oncotype test, a feasibility study has suggested
that neoadjuvant endocrine therapy is effective,
implying that it is preferable to adjuvant
chemotherapy for lower-risk patients [56].
PRIMARY ENDOCRINE THERAPY
Patients with primary breast cancer should be
offered curative surgery irrespective of age and
ER status—provided they are fit enough for
surgery [57]. However, data from UK clinical
practice in the previous decade suggest that up
Fig. 2 Aromatase inhibitor adjuvant trial designs
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to 40% of women over 70 years of age present-
ing with ER? disease had primary endocrine
therapy (PET) instead of initial surgery [58].
Selection of initial therapy is dictated by
patient fitness, co-morbidities and patient
choice. Fitness for surgery is assessed clinically,
and the decision made is often a factor of
complex physical and psychosocial considera-
tions [59].
Not surprisingly, randomised trials of PET
versus initial surgery show that removal of the
primary tumour (followed by optimal adjuvant
therapy) provides better local and regional
control than PET [60]. Nearly all patients who
have PET will eventually experience progression
of the primary tumour due to the development
of endocrine resistance. Furthermore, up to 20%
of patients who receive PET will go on to require
surgery as a result of disease progression [61].
In 2007, a Cochrane review analysed seven
randomised trials of PET versus initial surgery in
older women (above 70 years at diagnosis) [62].
All but one of the trials (the Nottingham EPSII
study) began before the routine use of ER status
to select for endocrine therapy. Despite this, the
Cochrane meta-analysis found no overall sur-
vival advantage for initial surgery over PET. In
2014, repeated meta-analysis confirmed that
these data remain valid at long-term follow-up
[60].
At the end of 2007, the ESTEeM study (En-
docrine with or without Surgical Therapy for
Elderly women with Mammary cancer) was
established to provide definitive assessment of
PET as a safe and effective breast cancer treat-
ment in older women. Inclusion criteria speci-
fied tumours of moderate or strongly positive
ER expression by IHC. Unfortunately, the study
closed early because of a low rate of patient
recruitment to the trial.
In the absence of randomised data from
ESTEeM, the effect of selecting patients for PET
based on ER status is clearly demonstrated by
comparison of the Nottingham Elderly Primary
Series randomised trials I and II [61, 63].
In EPSI, patients were not selected for treat-
ment according to ER status. In line with the
expected proportion of ER-positive tumours in
the patient cohort, 74% of patients in the EPSI
study derived clinical benefit from primary
tamoxifen at 6 months. In the EPSII study,
patients were selected for PET according to ER
status, using ER H score[ 100 as the cut-off for
positivity. The rate of clinical benefit corre-
spondingly improved, to 97% at 6 months.
Analysis of a large retrospective clinical cohort
Fig. 3 The primary use of endocrine therapies: response rates in neoadjuvant studies [53]
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treated at Nottingham (N = 1078) indicates that
not only ER status but also the degree of ER
positivity is important in selecting patients for
PET. In this retrospective cohort, clinical benefit
with PET reached 100% for those patients who
had tumours with ‘very high’ ER positivity (de-
fined as H score[250) [64] (see Table 4).
The importance of degree of ER positivity is
particularly relevant in the context of older
women with primary breast cancer. It has been
shown that primary breast cancer in older peo-
ple has biological characteristics distinct from
those in younger patients. For example, the
proportion of ER-positive disease and degree of
ER positivity both increase with age (see Fig. 4)
[65]. This suggests that older patients with pri-
mary breast cancer are more likely to have ER-
rich tumours and therefore derive clinical ben-
efit from PET.
The challenge remains to select the right
patients for PET using standardised clinical
assessment tools to assess frailty, combined
with biomarkers in addition to ER status to pick
out distinct biological features of those likely to
derive benefit from PET [66].
CHEMOPREVENTION
Chemoprevention in breast cancer uses endo-
crine therapy to reduce the risk of breast cancer
developing in patients considered at high risk.
Currently, only patients at high risk are con-
sidered for chemoprevention. This is deter-
mined by family history and presence of
BRCA1/2 and TP53 mutation.
Chemoprevention has also been used for high-
risk pathologies including atypical ductal
hyperplasia, atypical lobular hyperplasia and
lobular carcinoma in situ [67]. An expanded
role for endocrine therapy in breast cancer
prevention has been explored on the basis of
data showing reduced incidence of contralateral
breast cancer in large adjuvant endocrine ther-
apy studies.
In the Early Breast Cancer Trialists’ Collabo-
rative Group (EBCTCG) meta-analysis of ran-
domised adjuvant trials, 5 years of tamoxifen
decreased the rate of contralateral breast cancer
from 4.7% to 2.6% [68]. This equates to a pro-
portional reduction of 47%, although it should
be noted that ER status was not routinely
assessed to select patients for adjuvant tamox-
ifen at the time of all reviewed trials. Subse-
quent meta-analysis of adjuvant AI trials, all of
which did select patients by ER status, revealed
a 40% reduction with AIs at 5 years versus
tamoxifen [69], reducing the incidence from
2.0% to 1.2% [69].
These preliminary data enabled the hypoth-
esis that chemoprevention would reduce breast
cancer incidence to be tested in prospective
trials. Similar to therapeutic studies, the con-
cept of balancing efficacy and tolerability (tox-
icity) is key to chemoprevention strategies.
In terms of efficacy, all the pivotal trials of
breast cancer chemoprevention demonstrated a
reduction in breast cancer incidence in the
experimental arm [70, 71]. For example, in the
tamoxifen chemoprevention trials, breast can-
cer incidence was reduced by 44% in ER-positive
patients [71]. Meta-analysis of trials including
Table 4 Selecting patients for primary endocrine therapy according to degree of ER positivity increases the proportion who
have clinical beneﬁt, and reduces the rate of de novo resistance
All ‡ 70 years on primary endocrine therapy (stage 1/2 disease) Chakrabartia Johnstonb Syedc
ER H score Unselected H C 100 H C 250
N 68 100 121
CB (at 6 months) 74% 97% 100%
PD (at 6 months) (de novo resistance) 26% 3% 0%
a Chakrabarti et al. [63]
b Johnston et al. [61]
c Syed et al. [64]
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AI chemoprevention trials demonstrates a clear
benefit for AIs over tamoxifen [70]. This meta-
analysis compared relative risk (RR), defined as
the ratio between the incidence of breast cancer
or serious adverse events in the experimental
versus control arm. For AIs, RR was 0.468 [95%
confidence interval (CI) 0.346–0.634] compared
to 0.708 (95% CI 0.595–0.842) for tamoxifen.
This analysis highlights the importance of
balancing efficacy with tolerability (toxicity) in
chemoprevention. In all studies, the reduction
in breast cancer incidence came at the expense
of greater incidence of the known complica-
tions of endocrine therapies, e.g. loss of bone
mineral density on AIs. Serious toxicities on
SERMs include thromboembolic events, which
were significantly increased across the studies
(odds ratio = 1.73, p\0.0001) [71]. In the trials
involving SERMs, rate of endometrial cancer
was significantly increased (hazard ratio = 1.56,
1.13–2.14). This effect was seen mainly in the
tamoxifen studies, and no effect on endometrial
cancer incidence was seen with raloxifene.
Whilst alternative SERMs such as raloxifene
have demonstrated favourable benefit–risk
ratios over tamoxifen and AIs in chemopre-
vention studies, they lack data from large
adjuvant studies, which may limit their uptake
into standard clinical practice.
The role of tamoxifen and AIs in chemopre-
vention has yet to be fully defined. One out-
standing question from the trials is whether this
reduction leads consistently to a reduction in
overall survival. An alternative hypothesis is
that chemoprevention delays but does not pre-
vent breast cancer. Long-term follow-up of the
prospective trials is required to resolve this
question.
Ultimately, chemoprevention with endo-
crine therapy will play only part of the role in
preventing breast cancer. BRCA-related cancers
are predominantly ER negative, hence chemo-
prevention strategies also involve alternative
modalities such as prophylactic mastectomy.
Young women at high risk of developing breast
cancer are most likely to benefit from
Fig. 4 The relative proportion of ER-positive primary breast cancer increases with age at diagnosis Reprinted from Ref.
[65]. Copyright (2008), with permission from Elsevier
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chemoprevention. The challenge remains to
define this group so that clinicians can make
informed decisions with patients.
CONCLUSIONS AND FUTURE
DIRECTIONS
Endocrine therapy is the mainstay of treatment
of ER-positive breast cancer, with established
clinical utility in advanced disease and in the
adjuvant and neoadjuvant settings. Rational
combination of endocrine therapy with ovarian
suppression and newer targeted therapies has
maximised efficacy in specific patient
subgroups.
Novel therapies have reached the clinic in
the first-line advanced setting, and their role is
likely to expand into adjuvant and neoadjuvant
treatment. Inhibitors of mTOR and CDK4/6 are
currently being explored in the adjuvant setting
in combination with endocrine therapy
[72, 73].
In the older population, who comprise the
majority of breast cancer patients, such devel-
opments may help redefine the role of primary
endocrine therapy, alone or in combination
with emerging targeted agents. In younger
patients at high risk of developing breast cancer,
the role of chemoprevention is likely to expand
in small increments to larger groups with well-
defined risk factors.
Irrespective of the clinical setting, the
detection of endocrine treatment failure or
resistance is likely to have a substantial impact
on future clinical practice. It has been demon-
strated that mutations in ESR1, the gene
encoding ER, are acquired secondary to endo-
crine therapy [74]. Similarly, amplification of
CYP19 is a potential resistance mechanism that
allows ER? breast cancer cells to escape aro-
matase inhibition [75]. Detection of these
genetic aberrations in serum has the potential
to detect treatment failure or resistance at an
earlier stage and influence clinical decision-
making.
There is a multiplicity of therapeutic strate-
gies for ER-positive breast cancer, especially in
the advanced setting, where patients are likely
to have received prior AI or tamoxifen as part of
adjuvant treatment. Despite advances in our
understanding of resistance mechanisms and
the introduction of novel targeted agents, the
only biomarker to select patients for endocrine
therapy is expression of the driving transcrip-
tion factor, ER. The challenge for clinicians is to
interpret the available data and select the best
strategy for ER-targeted therapy for individual
patients.
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